{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:05:28Z","timestamp":1760299528256,"version":"3.41.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T00:00:00Z","timestamp":1486771200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10157-016-1379-0","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T04:41:18Z","timestamp":1486788078000},"page":"858-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure"],"prefix":"10.1007","volume":"21","author":[{"given":"Mari","family":"Katsumata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-3652","authenticated-orcid":false,"given":"Nobuhito","family":"Hirawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Kagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Ehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Saka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Yatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Toya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,11]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"crossref","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273\u20138.","DOI":"10.1152\/ajprenal.00195.2005"},{"key":"1379_CR2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"1379_CR3","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690\u20136.","journal-title":"Circulation"},{"key":"1379_CR4","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","volume":"291","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Gattis WA, O\u2019Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963\u201371.","journal-title":"JAMA"},{"key":"1379_CR5","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"1379_CR6","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1210\/en.2004-1590","volume":"146","author":"T Miyazaki","year":"2005","unstructured":"Miyazaki T, Yamamura Y, Onogawa T, Nakamura S, Kinoshita S, Nakayama S, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology. 2005;146:3037\u201343.","journal-title":"Endocrinology"},{"key":"1379_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","volume":"2","author":"GM Felker","year":"2009","unstructured":"Felker GM, O\u2019Connor CM, Braunwald E, Heart Failure Clinical Research Network, I. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2:56\u201362.","journal-title":"Circ Heart Fail"},{"key":"1379_CR8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1379_CR9","first-page":"563","volume":"4","author":"EC Cheriex","year":"1989","unstructured":"Cheriex EC, Leunissen KM, Janssen JH, Mooy JM, van Hooff JP. Echography of the inferior vena cava is a simple and reliable tool for estimation of \u2018dry weight\u2019 in haemodialysis patients. Nephrol Dial Transplant. 1989;4:563\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"1379_CR10","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T, Tolvaptan I. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S19\u201331.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 1","key":"1379_CR11","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan I. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33\u201345.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1379_CR12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1536\/ihj.14-190","volume":"55","author":"E Sato","year":"2014","unstructured":"Sato E, Nakamura T, Amaha M, Nomura M, Matsumura D, Yamagishi H, et al. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J. 2014;55:533\u20138.","journal-title":"Int Heart J"},{"key":"1379_CR13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00004424-199911000-00004","volume":"34","author":"SN Heyman","year":"1999","unstructured":"Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol. 1999;34:685\u201391.","journal-title":"Invest Radiol"},{"key":"1379_CR14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1523-1755.2001.060002607.x","volume":"60","author":"M Goldfarb","year":"2001","unstructured":"Goldfarb M, Abassi Z, Rosen S, Shina A, Brezis M, Heyman SN. Compensated heart failure predisposes to outer medullary tubular injury: studies in rats. Kidney Int. 2001;60:607\u201313.","journal-title":"Kidney Int"},{"key":"1379_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/AC.70.2.3073514","volume":"70","author":"A Tanaka","year":"2015","unstructured":"Tanaka A, Katsuno T, Ozaki T, Sakata F, Kato N, Suzuki Y, et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol. 2015;70:217\u201323.","journal-title":"Acta Cardiol"},{"key":"1379_CR16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ki.1987.192","volume":"32","author":"M Inoue","year":"1987","unstructured":"Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 1987;32:198\u2013203.","journal-title":"Kidney Int"},{"key":"1379_CR17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0022-3565(25)20166-5","volume":"252","author":"KA Kirchner","year":"1990","unstructured":"Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide\u2014a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther. 1990;252:1097\u2013101.","journal-title":"J Pharmacol Exp Ther"},{"key":"1379_CR18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s10157-013-0788-6","volume":"17","author":"T Otsuka","year":"2013","unstructured":"Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol. 2013;17:834\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"1379_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","volume":"53","author":"W Mullens","year":"2009","unstructured":"Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589\u201396.","journal-title":"J Am Coll Cardiol"},{"key":"1379_CR20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2215\/CJN.06540810","volume":"6","author":"A Blanchard","year":"2011","unstructured":"Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, et al. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin J Am Soc Nephrol. 2011;6:753\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1379_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1536\/ihj.13-221","volume":"55","author":"T Imamura","year":"2014","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J. 2014;55:131\u20137.","journal-title":"Int Heart J"},{"key":"1379_CR22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1253\/circj.CJ-12-1328","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013;77:1208\u201313.","journal-title":"Circ J"},{"key":"1379_CR23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000381859","volume":"130","author":"H Iwatani","year":"2015","unstructured":"Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, et al. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron. 2015;130:8\u201312.","journal-title":"Nephron"},{"key":"1379_CR24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jjcc.2012.09.002","volume":"60","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012;60:462\u20139.","journal-title":"J Cardiol"},{"key":"1379_CR25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11897-010-0035-3","volume":"8","author":"G Valania","year":"2011","unstructured":"Valania G, Singh M, Slawsky MT. Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists? Curr Heart Fail Rep. 2011;8:198\u2013205.","journal-title":"Curr Heart Fail Rep"},{"key":"1379_CR26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.111.065391","volume":"125","author":"CP Kovesdy","year":"2012","unstructured":"Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012;125:677\u201384.","journal-title":"Circulation"},{"key":"1379_CR27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/qjmed\/hcn061","volume":"101","author":"F Gankam Kengne","year":"2008","unstructured":"Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008;101:583\u20138.","journal-title":"QJM"},{"key":"1379_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","volume":"25","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1\u201313.","journal-title":"Cardiovasc Drug Rev"},{"key":"1379_CR29","doi-asserted-by":"crossref","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, et al. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 2015.","DOI":"10.1016\/j.cardfail.2015.08.207"},{"key":"1379_CR30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169\u201374.","journal-title":"J Cardiol"},{"key":"1379_CR31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","volume":"67","author":"K Kimura","year":"2016","unstructured":"Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399\u2013405.","journal-title":"J Cardiol"},{"key":"1379_CR32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jcph.197","volume":"53","author":"S Suzuki","year":"2013","unstructured":"Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53:1277\u201385.","journal-title":"J Clin Pharmacol"},{"key":"1379_CR33","doi-asserted-by":"crossref","first-page":"704289","DOI":"10.1155\/2014\/704289","volume":"2014","author":"S Suzuki","year":"2014","unstructured":"Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial. Biomed Res Int. 2014;2014:704289.","journal-title":"Biomed Res Int"},{"key":"1379_CR34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1291\/hypres.31.433","volume":"31","author":"E Imai","year":"2008","unstructured":"Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008;31:433\u201341.","journal-title":"Hypertens Res"},{"key":"1379_CR35","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1379-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T07:53:18Z","timestamp":1749973998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1379-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2017,2,11]]}}}